Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Cancers|May 13, 2023
Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual EvaluationsCaroline Burgard, Florian Rosar, Robert J Marlowe, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 6, 2023
Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancerFlorian Rosar, Fadi Khreish, Robert J Marlowe, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 3, 2025
Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapyCaroline Burgard, Marie D Muenzenberg, Arne Blickle, et al.
Clinical Nuclear Medicine|May 21, 2024
225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective RegistryFlorian Rosar, Caroline Burgard, Luna Vanessa Rohloff, et al.
Theranostics|March 20, 2024
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|September 13, 2025
Assessment of scintigraphic imaging with Terbium-161: A visual and quantitative analysisFlorian Rosar, Sven Petto, Sebastian Ganz, et al.
Cancers|March 11, 2023
Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" ExperienceCaroline Burgard, Manuela A Hoffmann, Madita Frei, et al.
EJNMMI Radiopharmacy and Chemistry|December 11, 2024
Development of a homotrimeric PSMA radioligand based on the NOTI chelating platformSebastian Martin, Moritz-Valentin Schreck, Tobias Stemler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2024
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopeniaMoritz B Bastian, Maike Sieben, Arne Blickle, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2025
Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)Moritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
Pageof 7